Trial Profile
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study of Daikenchuto (TU-100) in Subjects With Moderate Crohn's Disease
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs TU 100 (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Sponsors Tsumura
- 10 Mar 2014 According to the ClinicalTrials.gov record, status changed from recruiting to discontinued.
- 10 Jan 2013 Planned End Date changed from 1 Nov 2012 to 1 Aug 2013 as reported by ClinicalTrials.gov.
- 11 May 2012 Additional lead trial investigators added as reported by ClinicalTrials.gov.